Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells.

@article{Hong2003BetaglucanFA,
  title={Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells.},
  author={Feng Hong and Richard D. Hansen and Jun Yan and Daniel J. Allendorf and Jarek T. Baran and Gary R Ostroff and Gordon D. Ross},
  journal={Cancer research},
  year={2003},
  volume={63 24},
  pages={9023-31}
}
The tumor-killing mechanisms available to monoclonal antibodies (mAbs; e.g., antagonism of growth factor receptors, antibody-dependent cell-mediated cytotoxicity) limit efficacy. Previous studies suggested that i.v. beta-glucan might function as an adjuvant for antitumor mAbs. beta- Glucan had been shown to function via the iC3b-receptor complement receptor 3 (CR3; CD11b/CD18) thereby enhancing leukocyte killing of tumor cells coated with iC3b via naturally occurring antitumor antibodies… CONTINUE READING
64 Citations
46 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 64 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 46 references

Rituximab: a review of its use in non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia

  • G. L. Plosker, D. P. Figgitt
  • Drugs,
  • 2003

Similar Papers

Loading similar papers…